Evidence map›Paper›PMID 19022862›Full record

ArticleBrain : a journal of neurology2009

Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures.

D T Okuda, R Srinivasan, J R Oksenberg, D S Goodin, S E Baranzini, A Beheshtian, E Waubant, S S Zamvil, D Leppert, P Qualley and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 4 pooled it
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 170 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Aggressive multiple sclerosis (1): Towards a definition of the phenotype.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020
    Article
  15. Article
  16. Article
  17. Biomarkers in Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

D T OkudaUCSF Multiple Sclerosis Center, University of California, San Francisco, San Francisco, California 94117, USA.
R Srinivasan
J R Oksenberg
D S Goodin
S E Baranzini
A Beheshtian
E Waubant
S S Zamvil
D Leppert
P Qualley
R Lincoln
R Gomez
S Caillier
M George
J Wang
S J Nelson
B A C Cree
S L Hauser
D Pelletier
Multiple Sclerosis Center of Atlanta · USMultiple Sclerosis Foundation · USUniversity of California, San Francisco · USKlinik und Poliklinik für Neurologie · DE

Funding

A Haplotype Map for Multiple SclerosisR01NS049477 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L · 2005 to 2014
$15.3M
Systemic Lupus Erythematosus and Ulcerative Colitis StudyU19AI067152 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KLARESKOG, LARS · 2005 to 2009
$10.1M
GENE LINKAGE STUDY OF MULTIPLE SCLEROSIS SIBLING PAIRSR01NS026799 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L, OKSENBERG, JORGE R. · 1989 to 2018
$6.8M
CSR NIH HHS RG#3517NIAID NIH HHS AI067152NIAID NIH HHS U19 AI067152NINDS NIH HHS NS26799NINDS NIH HHS R01 NS026799NINDS NIH HHS R01 NS049477
6 · The paper itself

Abstract

Genetic susceptibility to multiple sclerosis (MS) is associated with the human leukocyte antigen (HLA) DRB1*1501 allele. Here we show a clear association between DRB1*1501 carrier status and four domains of disease severity in an investigation of genotype-phenotype associations in 505 robust, clinically well characterized MS patients evaluated cross-sectionally: (i) a reduction in the N-acetyl-aspartate (NAA) concentration within normal appearing white matter (NAWM) via (1)HMR spectroscopy (P = 0.025), (ii) an increase in the volume of white matter (WM) lesions utilizing conventional anatomical MRI techniques (1,127 mm(3); P = 0.031), (iii) a reduction in normalized brain parenchymal volume (nBPV) (P = 0.023), and (iv) impairments in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT-3) performance (Mean Z Score: DRB1*1501+: 0.110 versus DRB1*1501-: 0.048; P = 0.004). In addition, DRB1*1501+ patients had significantly more women (74% versus 63%; P = 0.009) and a younger mean age at disease onset (32.4 years versus 34.3 years; P = 0.025). Our findings suggest that DRB1*1501 increases disease severity in MS by facilitating the development of more T2-foci, thereby increasing the potential for irreversible axonal compromise and subsequent neuronal degeneration, as suggested by the reduction of NAA concentrations in NAWM, ultimately leading to a decline in brain volume. These structural aberrations may explain the significant differences in cognitive performance observed between DRB1*1501 groups. The overall goal of a deep phenotypic approach to MS is to develop an array of meaningful biomarkers to monitor the course of the disease, predict future disease behaviour, determine when treatment is necessary, and perhaps to more effectively recommend an available therapeutic intervention.

Indexed as

AdolescentAdultAgedBrainCognition DisordersFemaleGenetic Predisposition to DiseaseGenotypeHeterozygoteHistocompatibility TestingHLA-DR AntigensHLA-DRB1 ChainsHumansImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMagnetic Resonance SpectroscopyHLA-DR AntigensHLA-DRB1*15:01 antigenHLA-DRB1 Chains

Identifiers

PMID19022862
PMCPMC2638695
OpenAlexW2095839641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.